valu usd unless otherwis note
view four segment particip deliv strong
ahead consensu estim upper half organ
growth forecast realist start point
set estim rise confid manag abil
meet even exceed forecast narrow discount
large-cap med-tech peer rais pt reiter outperform
initi organ revenu growth forecast
includ fx forecast ww revenu mid-
point organ growth forecast bp lower
estim attribut differ two main factor first
revenu upsid rel estim rais base
bp second believ compani take
conserv stanc set expect cardiac vascular
group cvg revenu increas cc take consider
competit dynam key end market tavr de implant
believ cvg organ growth bp
mdt forecast repres increment contribut bp
ww organ growth cvg account mdt revenu
forecast cc ep growth includ fx-
relat benefit forecast non-gaap ep mid-
point revenu guidanc ebit margin guidanc impli
y/i ebit growth thu oper leverag account
differ revenu growth ep growth lower interest
expens share buyback convert ebit growth ep
growth model
result repres anoth solid perform across
portfolio ww revenu y/i cc almost
ident y/i growth estim upsid
came restor therapi group minim invas
therapi group non-gaap oper margin increas bp
bp non-gaap ep rbce
updat estim primarili fx new revenu ep
estim lower
previou estim reflect updat fx guidanc
estim organ revenu growth upsid
revenu estim like come cvg dg
increas price target reiter outperform mdt
quarterli result attain certain level consist
past quarter set asid hurrican impact
combin conserv revenu guid view
result compani meet beat consensu
revenu ep expect go forward believ mdt discount
peer narrow cours price target
base
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
set conserv revenu forecast
follow organ revenu growth
forecast growth guidanc assum
growth cvg mitg rtg double-digit growth
diabet group analysi indic top half
guidanc appropri start point cvg
diabet like sourc upsid rel
estim segment
focu emerg market pay dividend
emerg market key compon manag
growth emerg market continu offset
slower growth develop market
intermediate-risk label expans prove
import catalyst tavr market growth
report tavr growth ahead market past four
quarter label expans along launch
new valv evolut key catalyst
low-risk trial advanc well keep compani
cours win approv label next
number busi within segment
well restor therapi group rtg
neurovascular neurosurgeri advanc energi
worth highlight spine recov minim
invas therapi group mitg new product advanc
advanc stapl drive mid single-digit
growth surgic innov busi unit
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim key assumpt underli
ep estim revenu compound-annual-growth-rate
exclud neg impact
hurrican maria relat disrupt basi point
oper margin expans excess free
cash flow dividend deploy primarili
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu compound-annual-growth-rate
 achiev combin accret
 superior perform key product categori
pacemak brain therapi diabet basi
point oper margin expans
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli ep
estim revenu compound-annual-growth-rate period
basi point oper margin expans
meaning buy-back
price target base ep estim y/i mdt
current price-to-earnings multipl ep estim theefor pt assum
meaning multipl expans current level key assumpt underli
ep estim revenu compound-annual-growth-rate exclud neg impact
hurrican maria relat disrupt basi point oper margin
expans excess free cash flow dividend deploy
primarili share buy-back price target basi outperform rate
risk rate price target
lacklust growth key franchis growth increasingli support
stand-alon new product cycl includ attain performa quadripolar crt-d
reveal linq micra pacemak admir dcb corevalv evolut estim could
neg affect sale new product come expect
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur
weak util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
